HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.

HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.

Despite a typically good response to first-line combination chemotherapy, the prognosis for patients with advanced ovarian cancer remains poor because of acquired chemoresistance. The use of targeted therapies such as trastuzumab may potentially improve outcomes for patients with ovarian cancer. HER...

Full description

Bibliographic Details
Main Authors: Marianne Tuefferd, Jérôme Couturier, Françoise Penault-Llorca, Anne Vincent-Salomon, Philippe Broët, Jean-Paul Guastalla, Djelila Allouache, Martin Combe, Béatrice Weber, Eric Pujade-Lauraine, Sophie Camilleri-Broët
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2007-11-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2042515?pdf=render

Internet

http://europepmc.org/articles/PMC2042515?pdf=render

Similar Items